Related Experiment Video
Updated: Oct 4, 2025

Hypothalamic Kisspeptin Neurons as a Target for Whole-Cell Patch-Clamp Recordings
Published on: March 17, 2023
Does kisspeptin act as a neuropeptide or as an adipokine in obese people?
Suzanne J Abbas1, Fatimah S Abed2, Iqbal H Dhefer3
1Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kerbala, Kerbala, Iraq.
Objectives:
Obesity is a serious global issue with a massive impact on the health and life of people worldwide. Besides being a neuropeptide, kisspeptin is an important adipokine involved in regulating energy homeostasis and body weight. This study aims to clarify the underlying role of kisspeptin in obesity.
Methods:
This case-control study included 110 obese individuals with BMI of 33.45 ± 0.36 kg/m2 and 84 normal-weight individuals with BMI 21.35 ± 0.24 kg/m2. The individuals' ages ranged from 21 to 45 years (31.56 ± 0.67 year). Kisspeptin, neutrophil epithelial activating peptide (ENA-78), and ghrelin were determined using the enzyme-linked immunosorbent assay (ELISA) technique. Lipid profile parameters were determined using the commercial colorimetric techniques.
Results:
Plasma concentrations of kisspeptin and ENA-78 were significantly higher in obese subjects (kisspeptine of obese: 437.66 ± 34.96 pg/ml; kisspeptine of normal-weight: 250.10 ± 16.16 pg/ml, p< 0.0001; ENA-78 of obese: 144.80 ± 23.94 pg/ml; ENA-78 of normal-weight: 50.97 ± 3.91 pg/ml, p< 0.001). Ghrelin concentrations showed no significant difference between obese and normal-weight subjects. The lipid profile parameters significantly differed between obese and normal-weight subjects.
Conclusion:
Kisspeptin is associated with obesity. An increased mass of adipose tissue could be responsible not only for increased kisspeptin secretion but also for the increased ENA-78 secretion. Kisspeptin may act as an adipokine more than a neuropeptide in obese population. Further studies on humans are required to establish the underlying role of kisspeptin in adipocyte differentiation and lipogenesis.
Related Concept Videos
Regulation of Food Intake
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Cell Specific Gene Expression

